Merck & Co’s attempts to move its checkpoint inhibitor Keytruda into prostate cancer have been blocked once again, continuing a run of disappointing studies with immun
Battle lines are being drawn up in metastatic castration-resistant prostate cancer (mCRPC), with AstraZeneca and Merck & Co’s market-leading PARP inhibitor Lynparza fi
Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial.
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho